Skip to main content

Table 6 Upper limit of parasite positivity rates (PPRs) which could be observed on day 3

From: Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data

Variable

AL

ASAQ-FDC

DP

 

Day 3 PPR (95 % CI)

Maximum predicted riska

Day 3 PPR (95 % CI)

Maximum predicted riska

Day 3 PPR (95 % CI)

Maximum predicted riska

Age category

      

<1 year

0.79 (0.00–1.67)

6.50

0.67 (0.00–2.00)

7.69

0.68 (0.00–1.45)

6.00

1 to <5 years

0.54 (0.28–0.79)

4.30

0.70 (0.19–1.21)

6.00

0.83 (0.00–1.65)

6.35

5 to <12 years

0.69 (0.26–1.11)

6.00

0.32 (0.00–0.76)

4.11

0.70 (0.07–1.34)

6.00

≥12 years

0.49 (0.11–0.88)

4.76

0.13 (0.00–0.40)

4.00

0.48 (0.00–1.06)

5.66

Transmission

      

High

0.20 (0.03–0.37)

4.00

0.27 (0.06–0.48)

4.00

0.05 (0.00–0.15)

2.00

Low/moderate

0.79 (0.43–1.15)

6.00

0.65 (0.09–1.22)

6.00

1.28 (0.27–2.29)

8.00

Parasitaemia (x 1,000 parasites/μl)

      

<10

0.39 (0.18–0.60)

4.00

0.43 (0.00–0.91)

4.92

0.87 (0.00–1.81)

7.02

10 to <50

0.58 (0.30–0.86)

4.62

0.35 (0.00–0.72)

4.00

0.54 (0.01–1.08)

5.77

50 to <100

0.81 (0.32–1.30)

6.00

1.01 (0.20–1.83)

7.02

0.86 (0.00–1.85)

7.14

≥100

1.04 (0.35–1.74)

6.67

1.12 (0.00–2.25)

8.00

1.15 (0.13–2.17)

8.00

Study sample size

      

<50

1.02 (0.12–1.92)

10.34

0.78 (0.00–2.00)

10.71

0.00 (0.00–7.71)

20.68

50 to <100

0.72 (0.30–1.13)

6.00

0.55 (0.00–1.53)

6.00

0.25 (0.00–0.50)

4.00

100 to <200

0.90 (0.34–1.45)

4.62

0.88 (0.08–1.68)

5.00

1.43 (0.00–3.03)

7.01

≥200

0.25 (0.05–0.45)

1.75

0.18 (0.02–0.35)

1.50

0.70 (0.00–1.73)

4.00

Overall

0.58 (0.34–0.82)

4.41

0.54 (0.14–0.94)

5.08

0.77 (0.11–1.42)

6.00

  1. aThe maximum predicted risk is the day 3 PPR which could be observed assuming the worst case day 3 PPR, that is, the upper limit of day 3 PPR 95 % CI. For calculating the maximum predicted risk for age, transmission and parasitaemia, a minimum study sample size of 50 in a study was assumed. AL, artemether-lumefantrine; ASAQ-FDC, fixed dose combination; DP, dihydroartemisinin-piperaquine; PPR, parasite positivity rate